Related Experiment Video

Updated: Jun 4, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice

Young Lee1, May-Yun Wang, Xiu Quan Du

  • 1Touchstone Center for Diabetes Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Diabetes
|January 29, 2011
PubMed
Abstract

Insights

Blocking glucagon action prevents deadly diabetes complications in mice with insulin deficiency. This research highlights glucagon

Area of Science:

  • Endocrinology
  • Metabolic Research
  • Diabetes Pathophysiology

Background:

  • Insulin deficiency characterizes type 1 diabetes, leading to severe metabolic dysregulation.
  • The precise role of glucagon in the diabetic metabolic phenotype remains incompletely understood.
  • Glucagon's action is mediated through the glucagon receptor (Gcgr).

Purpose of the Study:

  • To elucidate the specific contribution of glucagon action to the metabolic phenotype observed in untreated insulin deficiency.
  • To investigate whether blocking glucagon signaling can ameliorate diabetic complications.

Main Methods:

  • Utilized glucagon receptor-null (Gcgr(-/-)) mice and wild-type (Gcgr(+/+)) controls.
  • Induced equivalent beta-cell destruction in both groups using streptozotocin.
  • Compared key clinical and metabolic parameters between Gcgr(-/-) and Gcgr(+/+) mice.

Main Results:

  • Wild-type mice with induced diabetes exhibited hyperglycemia, hyperketonemia, polyuria, and cachexia.
  • Gcgr(-/-) mice, despite comparable beta-cell loss, did not develop these diabetic manifestations.
  • Blocked glucagon action in Gcgr(-/-) mice normalized glucose levels and reduced free fatty acid and beta-hydroxy butyrate levels.

Conclusions:

  • Blocking glucagon action effectively prevents the lethal metabolic and clinical derangements associated with type 1 diabetes in mice.
  • Glucagon signaling is a critical driver of the severe phenotype in insulin-deficient states.
  • Targeting the glucagon receptor represents a potential therapeutic strategy for type 1 diabetes.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...